PARP1 and neoplasm: As a solo agent, rucaparib has been demonstrated to sensitize human cancer cells or xenograft tumours with mutated or epigenetically silenced BRCA1/2, indicating a potential role for PARP inhibitors in sporadic human cancers [186].